Medically reviewed by Jay N. Yepuri, MD PBC is a chronic liver disease that damages bile ducts and can lead to liver failure. You can get treatment for PBC to slow disease progression and manage ...

"We are pleased with our interactions with both the FDA and EMA," said Randy Milby, CEO of Tharimmune. "The recent regulatory feedback from the EMA builds on the previous positive interactions with ...

Cholangitis and cholecystitis are two conditions that share some similarities but have different causes and symptoms. Cholangitis affects the bile ducts, while cholecystitis affects the gallbladder.

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...

Nail clubbing, characterized by rounded, thickened, and downward-curved nails, serves as a subtle yet significant indicator ...

Scientists and clinician-scientists at the University of Birmingham will lead a major research programme to transform the ...

Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability Company expects to engage FDA on Phase 2 trial design and expects topline ...

The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes ...

"I wouldn't be here today without a donor, so I will always be forever grateful; it is a matter of life and death," said Dyer, two years on from his operation. "I had a very rare disease and I looked ...